Billable / Specific Code
ICD-10-CM C86.51 is the diagnosis code for Angioimmunoblastic T-cell lymphoma, in remission. This code falls under the section "Malignant neoplasms of lymphoid, hematopoietic and related tissue" within Chapter 2 — Neoplasms (C00-D49). It is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. Medical coders and healthcare providers use this code to document and classify diagnoses in electronic health records, insurance claims, and clinical databases.
Understanding where C86.51 sits in the ICD-10-CM classification helps ensure proper coding:
Yes, C86.51 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
C86.51 is the ICD-10-CM diagnosis code for "Angioimmunoblastic T-cell lymphoma, in remission". It is used by healthcare providers to classify and document this condition in medical records and insurance claims.
The parent code of C86.51 is C86.5 ("Angioimmunoblastic T-cell lymphoma"). C86.51 provides a more specific classification within this category.
C86.51 is located in Section C81-C96 — "Malignant neoplasms of lymphoid, hematopoietic and related tissue" within Chapter 2 of the ICD-10-CM Tabular List.
Use C86.51 when the patients documented diagnosis matches "Angioimmunoblastic T-cell lymphoma, in remission" and the clinical documentation supports this level of specificity. Always verify with the latest ICD-10-CM guidelines and payer requirements.
The ICD-10-CM code for Angioimmunoblastic T-cell lymphoma, in remission is C86.51.
Yes, C86.51 can be used as a primary diagnosis code since it is billable and specific.
C86.51 is in Chapter 2 of the ICD-10-CM Tabular List.
Yes, C86.51 is a valid ICD-10-CM code for the 2026 fiscal year, subject to official CMS updates.